Despite being granted an emergency use authorization, the Food and Drug Administration (FDA) revealed on Tuesday that the COVID-19 vaccines manufactured by Chinese company Sinovac Biotech are much suitable for those in the regular workforce.
Sinovac is the third vaccine company to secure EUA in the Philippines following AstraZeneca of the United Kingdom and Pfizer-BioNTech of the US/Germany.
According to FDA Director-General Eric Domingo, the Sinovac vaccine has a 65 to 91 percent efficacy rate for those who belong to the regular workforce compared to health workers and senior citizens who will only receive 50.4-percent protection from the vaccine.
The FDA official earlier said that it should only be received by healthy people aged 18-59 with an interval of four weeks between doses.
However, despite lower efficacy, Domingo said Sinovac rated well in terms of side effects as it is a good option for those with allergies since there is a low possibility that a person will develop severe allergies or anaphylaxis after inoculation.
The Philippines is currently expecting the arrival of the 600,000 Sinovac doses donated by the Chinese government this week.